From GlobeNewswire: 2025-05-30 07:00:00

Novasight’s value proposition is validated by new U.S. intracoronary imaging guidelines and recent peer-reviewed research. An upsized $20 million financing round led by U.S. institutional investors will fund key milestones, including the planned commercial launch of the next-generation Novasight Hybrid™ System in H1 2026. U.S. FDA 510(k) submission is on track for Q3 2025.

Conavi Medical Corp. announced financial results for Q2 2025, recording revenue of $58,000. Operating expenses were approximately $5.6 million, with an operating loss of $5.4 million. Net loss was $3.1 million, or $0.07 per common share. Cash and cash equivalents were approximately $1.0 million as of March 31, 2025, excluding the $20 million raised in April 2025.

The Company completed the design freeze of the next-generation Novasight Hybrid System in January 2025. New intracoronary imaging guidelines from leading medical organizations validate Novasight’s technology. The Company also announced its common shares’ uplisting to the OTCQB and closed an upsized equity offering for $20 million in April 2025 to fund operations.



Read more at GlobeNewswire:: Conavi Medical Reports Fiscal Q2 2025 Interim Results and